RxDoctor Payments DataLook up a doctor →

Sachida Manocha, MD

Interventional Pain Medicine · Newark, OHNPI 1821036435

Payments from drug & device makers

$10,012in general payments, 2019–2025

Across 561 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Collegium Pharmaceutical, Inc.$759
  • Supernus Pharmaceuticals, Inc.$514
  • Abbott$394
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$2112%
  • Food & beverage$9,80198%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,012 in reported general payments places this provider in the 60th percentile of 67 interventional pain medicine providers in Ohio.

See all interventional pain medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$177,128
Medicare patients
149
Services billed
30,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide24$60,259
Buprenorphine184$46,662
OzempicSemaglutide36$33,324
Xtampza ErOxycodone Myristate61$28,389
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,537$21,655
UbrelvyUbrogepant16$18,930
MovantikNaloxegol Oxalate41$16,598
Dantrolene Sodium102$6,534
BelbucaBuprenorphine Hcl16$6,125
ButransBuprenorphine15$5,522
Gabapentin362$4,926
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen230$1,857
Baclofen88$1,534
Ondansetron Hcl21$1,372
Topiramate252$1,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,299$60,25924 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$759$34,51477 claims
AbbVieUbrelvy$1,479$18,93016 claims
Redhill Biopharma Inc.Movantik$37$16,59841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 67 interventional pain medicine providers in Ohio.

Other interventional pain medicine in Newark

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →